Press Release
April 6, 2021

Goodwin Expands West Coast Platform With Life Sciences Partners Can Cui And Steven Green

Global law firm Goodwin today announced that Dr. Can Cui and Steven Green joined the firm’s Life Sciences practice as partners, resident in the San Francisco and Silicon Valley offices, respectively.

“We are thrilled to expand our California team as we continue to build a global destination practice for innovative life sciences companies and investors,” said Mitchell Bloom, chair of Goodwin’s Life Sciences practice. “Can and Steven are incredibly strong, multitalented lawyers who strengthen our fully integrated team of lawyers across our IP, licensing, collaborations, regulatory, and corporate practices, and reinforce our holistic approach to our ‘one-stop shop’ lifecycle practice.”

Dr. Cui serves as an external general counsel to life sciences companies in both the U.S. and China. His practice focuses on China-related life sciences transactions, including cross-border licensing, collaboration, and strategic partnerships, and M&A, and joint ventures. He has a successful track record of representing both licensors and licensees in U.S.–China licensing transactions and regularly represents life sciences companies and investors in intellectual property due diligence and Chinese regulatory matters. As a former scientist, he has strong research experience in both immune-oncology and virology, and holds a doctorate in biological chemistry and molecular pharmacology from Harvard University.

“The U.S. and China are the two largest life sciences markets in the world, and Goodwin’s comprehensive global offering adds significant value to companies operating in both markets,” said Dr. Cui. “I’m thrilled to join the firm's talented, collaborative team to deliver exceptional service to clients.”

Mr. Green advises emerging life sciences and technology companies on a full spectrum of business and legal issues throughout their corporate lifecycles. He has extensive experience advising clients on new company formations, fundraisings, mergers and acquisitions, and initial public offerings. Mr. Green also advises venture capital firms on structuring and executing investments into life sciences and technology companies.

“Goodwin’s seamless integration of its market-leading multidisciplinary life sciences platform allows the firm to provide the best possible service to clients,” said Mr. Green. “I’m excited to be a part of a firm with an incredible culture and commitment to further expand its capabilities in California and beyond.”

U.S. News — Best Lawyers’ 2021 edition named Goodwin the Biotechnology Law Firm of the Year for the sixth time. LMG Life Sciences also named Goodwin firm of the year for 2020 in the corporate, lifecycle, and intellectual property categories. Mergermarket’s Deal Drivers FY 20 reports named Goodwin the number one firm (by deal count) for Pharma, Medical, and Biotech M&A in North America and the number two firm (by value) for Pharma, Medical, and Biotech M&A in Europe, the Middle East, and Africa. Chambers UK 2021 recognized Goodwin’s Life Sciences UK practice for the first time in 2020 and The British Legal Awards named Goodwin’s UK team the Life Sciences Team of the Year in 2020.

Goodwin’s Life Sciences practice represents leading public and private life sciences companies and investors across their entire life cycles — including financings, capital market transactions, M&A, collaborations and licensing, intellectual property, and regulatory matters.